Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(7 sites)

United States

University of Florida, Gainesville, Florida

Ann and Robert H Lurie Childs Hosp, Chicago, Illinois

Levine Childrens Hospital, Charlotte, North Carolina

Cincinnati Childrens Hospital, Cincinnati, Ohio

Univ Hosp Cleveland Medical Center, Cleveland, Ohio